Title | Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Halper-Stromberg A, Nussenzweig MC |
Journal | J Clin Invest |
Volume | 126 |
Issue | 2 |
Pagination | 415-23 |
Date Published | 2016 Feb |
ISSN | 1558-8238 |
Keywords | Animals, Antibodies, Neutralizing, HIV Antibodies, HIV Infections, HIV-1, Humans, Remission Induction |
Abstract | Current antiretroviral drug therapies do not cure HIV-1 because they do not eliminate a pool of long-lived cells harboring immunologically silent but replication-competent proviruses - termed the latent reservoir. Eliminating this reservoir and stimulating the immune response to control infection in the absence of therapy remain important but unsolved goals of HIV-1 cure research. Recently discovered broadly neutralizing antibodies (bNAbs) exhibit remarkable breadth and potency in their ability to neutralize HIV-1 in vitro, and recent studies have demonstrated new therapeutic applications for passively administered bNAbs in vivo. This Review discusses the roles bNAbs might play in HIV-1 treatment regimens, including prevention, therapy, and cure. |
DOI | 10.1172/JCI80561 |
Alternate Journal | J. Clin. Invest. |
PubMed ID | 26752643 |
PubMed Central ID | PMC4731188 |
Grant List | UM1 AI100663 / AI / NIAID NIH HHS / United States P01 AI100148 / AI / NIAID NIH HHS / United States T32GM07739 / GM / NIGMS NIH HHS / United States AI100663-04 / AI / NIAID NIH HHS / United States AI100148-03 / AI / NIAID NIH HHS / United States F30 AI109830 / AI / NIAID NIH HHS / United States AI109830-02 / AI / NIAID NIH HHS / United States T32 GM007739 / GM / NIGMS NIH HHS / United States |
Submitted by kej2006 on June 6, 2018 - 4:11pm